CSL Limited, Johnson & Johnson Services, Inc., and Baxter are expected to Dominate the Global Human Fibrin Glue in 2021

Global Human Fibrin Glue Market is expected to grow with the CAGR of 9.2% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-human-fibrin-glue-market

The global human fibrin glue market is a highly consolidated market, including a specific number of key players. The market has witnessed increased strategic developments due to favorable market scenarios.

The major players dealing in the global human fibrin glue market are introducing a strong range of product providers, launching new products, and adopting strategic initiatives such as acquisition, agreement, business expansion, award, and recognition. This helped companies to maximize sales with an enhanced product portfolio.

For instance:

  • In August 2021, Baxter announced that its subsidiary Baxter Healthcare Corporation has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc. This has helped the company expand its Advanced Surgery Portfolio.

  • In December 2019, Johnson & Johnson Services, Inc. launched VISTASEAL Fibrin Sealant (Human) to help surgeons manage bleeding during surgery which contains a combination of fibrinogen and thrombin, clotting proteins found in human plasma. This has increased company’s product pipeline

CSL Limited is the dominating player in the global human fibrin glue market. The other key players existing in the market are Baxter, Johnson & Johnson Services Inc. Corza Health, Shanghai RAAS, Marquee Biosurgical, and Hualan Biological Engineering, Inc., among others.

Human Fibrin Glue MarketCSL LIMITED

CSL Limited founded in 1904, is headquartered in Pennsylvania, U.S. The company is focused on developing and delivering innovative therapies to treat people with serious and life-threatening medical conditions. The company operates its business via several business segments, including CSL Behring and Seqirus in which CSL Behring is the market-focused segment.

The company provides products via various product categories, such as Immunology, Hematology, Respiratory, Cardiovascular & Metabolic, and Transplant, in which Hematology, Solutions is market focused category.

For instance,

  • In June 2020, CSL acquired Vitaeris Inc., a clinical-stage biotechnology company to broaden its brand and product portfolio

The company has a presence across Asia-Pacific, Middle East & Africa, Latin America, and Europe. The company also has various subsidiaries, including CSL Limited (Australia), CSL Behring (U.S.), CSL Behring AG (Switzerland), CSL Behring (Germany), and Ruide (China), among others.

Johnson & Johnson Services, Inc.

Johnson & Johnson Services, Inc. was founded in 1961, headquartered in New Jersey, U.S. The company focuses on providing surgical technologies and solutions include sutures, staplers, energy devices, trocars, and hemostats, along with interventional ablation, robotics, and digital solutions. The company operates its business via several business segments Pharmaceuticals, Consumer, Medical Devices, in which Medical Devices are the market-focused segment.

The company provides products via various product categories such as Adjunctive Hemostats, Energy Sealing & Dissecting, Hernia Mesh & Fixation, Ligation, Magnetic Sphincter Augmentation, Microwave Ablation, Other Endoscopic Instruments, Surgical Stapling, Uterine & Pelvic, Vascular Access & Infection Control and Wound Closure in which Adjunctive Hemostats is market focused.

For instance,

  • In December 2019, Johnson & Johnson Services, Inc. launched VISTASEAL Fibrin Sealant (Human) to help surgeons manage bleeding during surgery which contains a combination of fibrinogen and thrombin, clotting proteins found in human plasma. This has increased company’s product pipeline.

The company has a wide presence across the Americas, Europe, Asia-Pacific, Middle East and Africa. The company also has various subsidiary companies Janssen-Cilag A/S (Denmark), Janssen Pharmaceutica (Pty.) Ltd. (South Africa), Johnson & Johnson Del Perú SA (Peru), Janssen-Cilag Farmacêutica Ltda. (Brazil), and Janssen Pharmaceuticals, Inc. (U.S.) among others among others

Baxter

Baxter was founded in 1931, headquartered in Illinois, U.S. The company mainly focuses on better healthcare solutions and access to care in the communities where people live and work. The company operates its business via several business segments, including Americas, EMEA, and APAC, in which Americas is the market-focused segment.

The company provides products via various product categories such as Critical Care, Hospital Care, Renal Care, Nutrient Care, and Surgical Care.

For instance,

  • In August 2021, Baxter announced that its subsidiary Baxter Healthcare Corporation has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc. This has helped the company expand its Advanced Surgery Portfolio.

The company has a presence across Latin America, North America, Europe, Asia-Pacific, Middle East, and Africa. The company also has various subsidiaries, including Baxter Corporation Englewood (Colorado), Baxter Healthcare Corporation (Delaware), Baxter Pharmaceutical Solutions LLC (Delaware), Baxter Healthcare Pty Ltd (Australia), and Baxter Belgium SPRL (Belgium), among others.